High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2 Yilong ZhangYousheng HuaKenneth K. Chan Original Article 14 March 2006 Pages: 561 - 569
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer Yasushi SatoTetsuji TakayamaYoshiro Niitsu Original Article 04 February 2006 Pages: 570 - 576
Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells Baoli QinHiroshi AriyamaShuji Nakano Original Article 11 March 2006 Pages: 577 - 584
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation Giacomo AllegriniAntonello Di Paolo Alfredo Falcone Original Article 06 May 2006 Pages: 585 - 593
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer Seiji NagashimaHiroshi SodaShigeru Kohno Original Article 07 March 2006 Pages: 594 - 600
A phase I trial of carboplatin and etoposide for elderly (≥75 year-old) patients with small-cell lung cancer Minoru FukudaHiroshi SodaMikio Oka Original Article 04 February 2006 Pages: 601 - 606
Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging Ruediger E. PortChristian SchusterPeter Bachert Original Article 28 February 2006 Pages: 607 - 617
Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells Annie HurtubiseRichard L. Momparler Original Article 17 June 2006 Pages: 618 - 625
Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy Demiana William FaltaosJean Sebastian HulotPhilippe Lechat Original Article 10 March 2006 Pages: 626 - 633
A phase II trial of O 6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma Christopher W. RyanM. Eileen DolanEverett E. Vokes Original Article 07 March 2006 Pages: 634 - 639
Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel Chih-Chuan ChangYu-Chuan LiangRu Chih C. Huang Original Article 17 March 2006 Pages: 640 - 653
Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma Her-Shyong ShiahYee ChaoTsang-Wu Liu Original Article 07 March 2006 Pages: 654 - 664
Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro Taisuke MoriYoshiyuki KinoshitaHideo Honjo Original Article 14 March 2006 Pages: 665 - 672
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors A. FeliciW. J. LoosM. J. A. de Jonge Original Article 17 March 2006 Pages: 673 - 680
Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib Juan Jose Perez-RuixoPeter ZannikosVladimir Piotrovsky Original Article 17 March 2006 Pages: 681 - 691
Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor Omar N. Al SafarjalaniReem RaisMahmoud H. el Kouni Original Article 10 March 2006 Pages: 692 - 698
The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice Anna M. E. BruynzeelPaula P. N. MulWim J. F. van der Vijgh Original Article 25 March 2006 Pages: 699 - 702
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group G. GossL. L. SiuL. K. Seymour Clinical Trial Report 10 March 2006 Pages: 703 - 710
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities Panagiotis A. KonstantinopoulosGerasimos P. VandorosAthanasios G. Papavassiliou Short Communication 25 January 2006 Pages: 711 - 715
Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor Michael FroehnerBettina Beuthien-BaumannManfred P. Wirth Short Communication 01 February 2006 Pages: 716 - 718